THOUSAND OAKS, Calif., Feb. 8, 2018 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced results from the XGEVA® (denosumab) Phase 3 ‘482 study, the largest international multiple myeloma trial for the prevention of skeletal-related events ever conducted (n=1,718), were published in The…
